Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

International Journal of Hematology

Volumn 93, Issue 2, 2011, Pages 206-212

  Pidala, Joseph ^a   Roman Diaz, Jaime ^a   Kim, Jongphil ^a   Nishihori, Taiga ^a   Perkins, Janelle ^a   Tate, Cheryl ^a   Ochoa Bayona, Jose L ^a   Field, Teresa ^a   Fernandez, Hugo F ^a   Tomblyn, Marcie ^a   Ayala, Ernesto ^a   Anasetti, Claudio ^a   Kharfan Dabaja, Mohamed A ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Allogeneic hematopoietic cell transplantation; Busulfan; Fludarabine; Rituximab

Indexed keywords

BUSULFAN; CD20 ANTIGEN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; ENGRAFTMENT; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOID; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 79952251879     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0747-x     Document Type: Article

References (18)

1. MA Kharfan-Dabaja C Anasetti ES Santos 2007 Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept Biol Blood Marrow Transpl 13 373 385 1:CAS:528:DC%2BD2sXkslWisbo%3D 10.1016/j.bbmt.2007. 01.075 (Pubitemid 46436729)
2. M Ghielmini E Zucca 2009 How I treat mantle cell lymphoma Blood 114 1469 1476 1:CAS:528:DC%2BD1MXhtVyiurzE 10.1182/blood-2009-02-179739 19556426
3. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematol Am Soc Hematology Educ Program. 2006;390-7.
4. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009;610-8.
5. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;233-42.
6. BD Cheson JP Leonard 2008 Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N Engl J Med 359 613 626 1:CAS:528:DC%2BD1cXpt12qtbw%3D 10.1056/NEJMra0708875 18687642
7. IF Khouri RM Saliba SA Giralt, et al. 2001 Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 3595 3599 1:CAS:528:DC%2BD3MXptFOjtrg%3D 10.1182/blood.V98.13.3595 11739162
8. IF Khouri P McLaughlin RM Saliba, et al. 2008 Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood 111 5530 5536 1:CAS:528:DC%2BD1cXnsVOkt7k%3D 10.1182/blood-2008-01-136242 18411419
9. B Glass 2008 Rituximab for graft-versus-host disease prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase II study Blood 112 689 690
10. V Ratanatharathorn B Logan D Wang, et al. 2009 Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation Br J Haematol 145 816 824 1:CAS:528:DC%2BD1MXosVartbc%3D 10.1111/j.1365-2141.2009.07674.x 19344418
11. V Ratanatharathorn L Ayash C Reynolds, et al. 2003 Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody Biol Blood Marrow Transpl 9 505 511 1:CAS:528:DC%2BD3sXnvF2gu7k%3D 10.1016/S1083-8791(03) 00216-7 (Pubitemid 38351794)
12. C Cutler D Miklos HT Kim, et al. 2006 Rituximab for steroid-refractory chronic graft-versus-host disease Blood 108 756 762 1:CAS:528: DC%2BD28XntFehu7w%3D 10.1182/blood-2006-01-0233 16551963 (Pubitemid 44061381)
13. MA Kharfan-Dabaja AR Mhaskar B Djulbegovic C Cutler M Mohty A Kumar 2009 Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis Biol Blood Marrow Transpl 15 1005 1013 1:CAS:528:DC%2BD1MXhtFCgs7vP 10.1016/j.bbmt.2009.04. 003
14. M de Lima D Couriel PF Thall, et al. 2004 Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 104 857 864 10.1182/blood-2004-02-0414 15073038 (Pubitemid 38970585)
15. Pidala J, Kim J, Anasetti C, et al. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transpl. [Epub ahead of print]; 2010.
16. D Przepiorka D Weisdorf P Martin, et al. 1995 1994 consensus conference on acute GVHD grading Bone Marrow Transpl 15 825 828 1:STN:280: DyaK28%2Fot1Ojtw%3D%3D
17. AH Filipovich D Weisdorf S Pavletic, et al. 2005 National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report Biol Blood Marrow Transpl 11 945 956 10.1016/j.bbmt.2005.09.004 (Pubitemid 41754712)
18. Kharfan-Dabaja M, Tate C, Perkins J, Fernandez H, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Ochoa-Bayona L, Sullivan D, Brand L, Poling W, Anasetti C. Rituximab is feasible to administer to allograft recipients with advanced CD20+ malignancies and does not affect timely hematopoietic engraftment. Biol Blood Marrow Transpl. 2008;14:121-2.